^(131)I标记物介入治疗肝癌的临床研究进展

Clinical Study of Internal Radiotherapy with Hepatic Intra-ar te rial Iodine-131 Labeled Material for Hepatocellular Carcinoma

目的 探讨13 1I标记物介入治疗原发性肝癌的临床价值。方法 复习相关文献 ,并作综述性报道。结果13 1I 碘化油 (13 1I LPD)及13 1I免疫生物制剂均能较好地聚集于肝癌组织 ,适应证较广 ,严重的不良反应少见 ,近期疗效肯定 ,部分临床试验证实治疗后患者的生存率有提高。结论 运用13

Objective To discuss the clinical val ue of internal radiation therapy with hepatic intra-arterial iodine-131 labele d material for the treatment of hepatocellular carcinoma (HCC). Methods This summarized paper was made on literatu re review. Results Iodine-131-lipiodol and several reported iodine-131-labeled antibodies to HCC associated antigens were concentrated in the foci of HCC with a high tumor-to-normal-tissue absorbed dose ratios. No s evere side effects occurred. It was used in various kinds of HCC patients, and m ostly showed a significant tumor response. Survival rate of HCC patients was rai sed in several clinical trials.Conclusion Internal radiotherapy with hepatic intr a-arterial iodine-131 labeled material may be considered as an effective metho d to treat HCC.